How to buy Cyclacel Pharmaceuticals stock | $7.17

Cyclacel Pharmaceuticals, Inc is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars.

Cyclacel Pharmaceuticals stock price (NASDAQ: CYCC)

Use our graph to track the performance of CYCC stocks over time.

Cyclacel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$7.17
52-week range	$3.12 - $11.42
50-day moving average	$5.88
200-day moving average	$7.04
Wall St. target price	$20.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.57

Buy Cyclacel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cyclacel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cyclacel Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclacel Pharmaceuticals price performance over time

Historical closes compared with the close of $7.17 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	24.26%
3 months (2021-05-04)	2.28%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Cyclacel Pharmaceuticals financials

Revenue TTM	$150,000
Gross profit TTM	$-4,759,000
Return on assets TTM	-24.14%
Return on equity TTM	-36.63%
Profit margin	0%
Book value	$5.20
Market capitalisation	$46.7 million

TTM: trailing 12 months

Shorting Cyclacel Pharmaceuticals shares

There are currently 717,635 Cyclacel Pharmaceuticals shares held short by investors – that's known as Cyclacel Pharmaceuticals's "short interest". This figure is 9.9% down from 796,417 last month.

There are a few different ways that this level of interest in shorting Cyclacel Pharmaceuticals shares can be evaluated.

Cyclacel Pharmaceuticals's "short interest ratio" (SIR)

Cyclacel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Cyclacel Pharmaceuticals shares currently shorted divided by the average quantity of Cyclacel Pharmaceuticals shares traded daily (recently around 74289.33747412). Cyclacel Pharmaceuticals's SIR currently stands at 9.66. In other words for every 100,000 Cyclacel Pharmaceuticals shares traded daily on the market, roughly 9660 shares are currently held short.

However Cyclacel Pharmaceuticals's short interest can also be evaluated against the total number of Cyclacel Pharmaceuticals shares, or, against the total number of tradable Cyclacel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclacel Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Cyclacel Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0892% of the tradable shares (for every 100,000 tradable Cyclacel Pharmaceuticals shares, roughly 89 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cyclacel Pharmaceuticals.

Find out more about how you can short Cyclacel Pharmaceuticals stock.

Cyclacel Pharmaceuticals share dividends

We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.

Have Cyclacel Pharmaceuticals's shares ever split?

Cyclacel Pharmaceuticals's shares were split on a 1:20 basis on 14 April 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.

Cyclacel Pharmaceuticals share price volatility

Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $3.12 up to $11.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 1.2231. This would suggest that Cyclacel Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Cyclacel Pharmaceuticals is owned by insiders or institutions?
Currently 2.257% of Cyclacel Pharmaceuticals shares are held by insiders and 53.228% by institutions. When does the fiscal year end for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals's fiscal year ends in December. Where is Cyclacel Pharmaceuticals based?
Cyclacel Pharmaceuticals's address is: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922 What is Cyclacel Pharmaceuticals's ISIN number?
Cyclacel Pharmaceuticals's international securities identification number is: US23254L6039 What is Cyclacel Pharmaceuticals's CUSIP number?
Cyclacel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 23254L108